Study #2022-0623
A Phase 3, open-label, randomized, two-part study comparing Gedatolisib in combination with Palbociclib and Fulvestrant to standard-of-care therapies in patients with HR-Positive, HER2-Negative advanced breast cancer previously treated with a CDK4/6 inhibitor in combination with non-steroidal aromatase inhibitor therapy (VIKTORIA-1)
MD Anderson Study Status
Enrolling
Treatment Agent
Gedatolisib, Palbociclib, Fulvestrant, Alpelisib
Description
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Cancer
Study phase:
Phase III
Physician name:
Rachel Layman
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-844-514-2993
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.